Press release
Cancer Immunotherapy Market to Reach US$ 261.74 Billion by 2033 at 7.9% CAGR, Driven by Rising Cancer Incidence and Advances in Checkpoint Inhibitors & Cell Therapies
Cancer Immunotherapy Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/cancer-immunotherapy-market?jd
Cancer Immunotherapy Market Key Mergers and Acquisitions
✦ January 2026: Merck & Co., Inc. acquired a biotech startup developing next-generation PD-1/L1 inhibitors to strengthen its oncology immunotherapy pipeline for advanced solid tumors.
✦ December 2025: Bristol-Myers Squibb Company completed a strategic acquisition of a cell therapy platform company to enhance its adoptive cell therapy offerings for hematologic malignancies and solid tumors.
✦ November 2025: AstraZeneca secured a licensing agreement with a gene-editing innovator to advance its CAR-T and TCR-T cell therapies for NSCLC and other indications.
Cancer Immunotherapy Market Key Industry Developments
☑️ January 2026: Merck & Co., Inc., Bristol-Myers Squibb Company, and AstraZeneca presented updated Phase III data for their checkpoint inhibitors and combination regimens in NSCLC, melanoma, and colorectal cancer at major oncology congresses, supporting expanded indications.
☑️ December 2025: Pfizer Inc. and F. Hoffmann-La Roche Ltd expanded access programs for their PD-1/PD-L1 inhibitors and bispecific antibodies, targeting earlier-line treatment in renal cell carcinoma and breast cancer.
☑️ November 2025: Novartis AG and Amgen Inc. advanced CAR-T therapies with improved manufacturing processes and safety profiles, gaining regulatory progress in hematologic and solid tumor indications.
Purchase the report to unlock market insights: https://www.datamintelligence.com/buy-now-page?report=cancer-immunotherapy-market
Cancer Immunotherapy Market Segmentation Analysis
By Type: Immune Checkpoint Inhibitors hold the largest share due to widespread use of PD-1/PD-L1 and CTLA-4 inhibitors in multiple solid tumors; Adoptive Cell Therapy grows fastest with CAR-T approvals expanding into solid tumors; Cancer Vaccines and Cytokines follow for targeted and adjuvant approaches; Other Immunotherapies include bispecifics, oncolytic viruses, and cytokines.
By Indication: Non-Small Cell Lung Cancer (NSCLC) accounts for the highest share with dominant checkpoint inhibitor use; Melanoma follows closely for high response rates to immunotherapy; Colorectal Cancer, Renal Cell Carcinoma, Breast Cancer, and Bladder Cancer grow steadily with emerging combinations; Others include head & neck, liver, and hematologic malignancies.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-immunotherapy-market?jd
Cancer Immunotherapy Market Key Players
✦ Merck & Co., Inc. - In January 2026, acquired a PD-1/L1 inhibitor biotech and presented new Keytruda combination data in NSCLC and melanoma, supporting label expansions and earlier-line use.
✦ Bristol-Myers Squibb Company - Completed acquisition of a cell therapy platform in December 2025 and advanced Opdivo/Yervoy combinations with positive Phase III results in renal cell carcinoma and colorectal cancer.
✦ AstraZeneca - Licensed a TCR-T therapy candidate in November 2025 and expanded Imfinzi and Imjudo use with new approvals in bladder cancer and other indications.
✦ Pfizer Inc. - Rolled out updated PD-L1 inhibitor data in late 2025 for breast cancer and NSCLC, focusing on combination strategies and real-world evidence generation.
✦ F. Hoffmann-La Roche Ltd - Advanced Tecentriq and bispecific antibody programs in December 2025 with new trial readouts in NSCLC, melanoma, and hematologic cancers.
Cancer Immunotherapy Market Regional Insights
North America dominates the Cancer Immunotherapy market with the largest revenue share, supported by high cancer incidence, rapid FDA approvals for checkpoint inhibitors and cell therapies, advanced oncology infrastructure, strong reimbursement for high-cost treatments, and significant R&D investment by leading biopharma companies.
Asia-Pacific is the fastest-growing region, fueled by rising cancer burden, increasing healthcare access and oncology centers, growing clinical trial participation, government initiatives for rare and advanced cancer care, and aggressive market entry by global players targeting NSCLC, melanoma, and other indications.
Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Immunotherapy Market to Reach US$ 261.74 Billion by 2033 at 7.9% CAGR, Driven by Rising Cancer Incidence and Advances in Checkpoint Inhibitors & Cell Therapies here
News-ID: 4356316 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Duchenne Muscular Dystrophy Treatment Market to Reach US$ 8.86 Billion by 2033 a …
According to DataM Intelligence, the global Duchenne Muscular Dystrophy Treatment market reached US$ 2.27 billion in 2024 and is expected to reach US$ 8.86 billion by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033, driven by increasing adoption of exon skipping therapies, strong pipeline progress in gene therapies and mutation suppression, rising diagnosis rates, and expanding access through hospital and retail pharmacies in North America and…
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market to Reach US$ 93.21 Mill …
According to DataM Intelligence, the global ESR1 mutated metastatic breast cancer diagnostics market size reached US$ 63.51 million in 2024 (from US$ 61.05 million in 2023) and is expected to reach US$ 93.21 million by 2033, growing at a CAGR of 4.4% during 2025-2033, driven by increasing incidence of endocrine therapy resistance in metastatic breast cancer, growing adoption of NGS-based testing for ESR1 mutations, expanding use of liquid biopsy (plasma)…
Healthcare Data Monetization Market to Reach US$ 1.33 Billion by 2031 at 14.9% C …
According to DataM Intelligence, the global Healthcare Data Monetization market was valued at approximately US$ 0.50 billion in 2024 and is projected to reach around US$ 1.33 billion by 2031, growing at a CAGR of 14.9% during the forecast period 2024-2031, driven by increasing volume of healthcare data, rising adoption of cloud deployment for scalable monetization, strong demand from pharmaceutical and biotech companies for real-world evidence, and rapid growth in…
Women Health Probiotic Supplement Market to Reach 18.31% CAGR, Driven by Rising …
According to DataM Intelligence, the global Women Health Probiotic Supplement market reached US$ 1,544.28 million in 2023 and is expected to reach US$ 5,009.04 million by 2031, growing at a CAGR of 18.31% during 2024-2031, driven by increasing focus on women's gut, vaginal, and urinary tract health, strong demand for targeted probiotic strains (Lactobacillus, Bifidobacterium), rapid growth in gummy and chewable formats, expanding e-commerce and specialty retail channels, and surging…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
